Perspective Therapeutics Stock (AMEX: CATX)

Perspective Therapeutics (AMEX:CATX) Stock, Quote.Headers.trade-ideas

Perspective Therapeutics

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Penny stock tips cover

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ACRS

CATX

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Penny,Stock,Investments,Taking,Off,Concept

BIOE

EXFY

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Bull and bear stock market index

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Intraday Update

Analyst Ratings

ETFs

$BTC

AMZN

SPDR Dow Jones Industrial Average ETF Trust

GOLD

IMNM

NKLA

SMTC

XLRE

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What&#39;s Driving Markets Thursday?

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

<p>H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. </p>
<p><strong>Buying $1000 In HRB:</strong> If an investor had bought $1000 of HRB stock 5 years ago, it would be worth <strong>$2,049.30</strong> today based on a price of $56.95 for HRB at the time of writing.</p>
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. </p>
<p><strong>Buying $1000 In APO:</strong> If an investor had bought $1000 of APO stock 10 years ago, it would be worth <strong>$4,546.33</strong> today based on a price of $122.16 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

<p>Citigroup  analyst Atif Malik   maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.</p>


Price Target

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

<p>During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Puma Biotechnology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Puma Biotechnology</h2>
<p>Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.</p>
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Challenges:</strong> Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-17.07%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-11.0%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-9.22%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Puma Biotechnology's ROA excels beyond industry benchmarks, reaching <strong>-2.17%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.17</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PBYI

Where Puma Biotechnology Stands With Analysts

<p>During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lennox Intl analyst ratings.</strong></a></p>
<h2>Delving into Lennox Intl's Background</h2>
<p>Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.</p>
<h3>Unraveling the Financial Story of Lennox Intl</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of <strong>2.81%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.95%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>51.98%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.92%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.72</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


10 Analysts Have This To Say About Lennox Intl

<p>Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. </p>
<p><strong>Buying $1000 In TSM:</strong> If an investor had bought $1000 of TSM stock 10 years ago, it would be worth <strong>$7,815.64</strong> today based on a price of $161.40 for TSM at the time of writing.</p>
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

<p>Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. </p>
<p><strong>Buying $100 In CNQ:</strong> If an investor had bought $100 of CNQ stock 5 years ago, it would be worth <strong>$279.38</strong> today based on a price of $34.42 for CNQ at the time of writing.</p>
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Betterware de Mexico SAPI analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
<p>Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.</p>
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>10.36%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.16%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>19.7%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.68%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>3.6</strong>, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

<p>Canaccord Genuity  analyst Dalton Baretto   maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.</p>


TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

<p>Canaccord Genuity  analyst Mike Mueller   maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.</p>


TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

<p>First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.</p>


Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

<p><strong>PayPal Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has <strong>20.55 million shares sold short</strong>, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.04 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

<p><strong>Owens-Corning's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has <strong>1.49 million shares sold short</strong>, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.27 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Owens-Corning's Recent Short Interest

<p><strong>Kohl's's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has <strong>40.73 million shares sold short</strong>, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 8.49 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


(KSS) - Analyzing Kohl's's Short Interest

<p><a href="https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393">https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393</a></p>
<p>Howard Schultz, the former Starbucks chief executive, is opposing a potential settlement between the company and activist investor Elliott Investment Management, in the latest sign of tension at the world's largest coffee chain. The quasi-founder of Starbucks has made his opposition to an Elliott settlement known to some board members, said people familiar with the matter. Schultz had criticised its leadership publicly in recent months despite no longer having a formal role at the company. He remains Starbucks's sixth-largest shareholder, with a holding of about $1.6bn. Elliott, known for being an aggressive investor, has built a sizeable minority stake in the $86bn company and has privately pushed for change in recent weeks, including board representation, in an attempt to revive Starbucks' lacklustre performance. Schultz and Elliott have not been in contact over this matter, one person said. Companies under pressure from activists such as Elliott often seek to negotiate agreements with them rather than face a public fight, but the status of any settlement discussions between Starbucks and Elliott remain unclear. "Howard left the board a year ago and in his limited contact with the board since, his input has always focused on the values and culture of Starbucks as the primary driver of success and performance," a person close to Schultz said. The billionaire former coffee machine salesman led the company three separate times — for about 14 years starting in 1986, then again from 2008 to 2017, and most recently as interim CEO from 2022 to 2023.&nbsp; He was succeeded as CEO last year by Laxman Narasimhan, who joined from UK-based consumer health and hygiene group Reckitt. Schultz remains chair emeritus but left the company's board and has said he does not have access to financial information.</p>
<p><br />Schultz, who has said he has no interest in returning as CEO, has remained vocal on the sidelines. This spring he criticised the company's performance on LinkedIn, penning an open letter that said senior leaders and board members needed "to spend more time with those who wear the green apron". He also made an appearance on business podcast Acquired in June, speaking about the history of Starbucks and his recommendations for management. "It hasn't been a great year for Starbucks," he said. "In fairness to Laxman, there's a lot of external issues that have contributed to the pressure, like on every company. But the company has not executed the way that I think it should have." "If the company is doing a drift towards mediocrity, I hold leadership, and the board responsible for that," he said later in the three-hour podcast.<br /><br />Starbucks's share price has fallen about 20 per cent since the start of 2024. The company cut its financial guidance in January and again in April, when it reported a 4 per cent decline in quarterly comparable store sales that was the first such drop since late 2020. It is due to announce results for its fiscal third quarter on Tuesday. Starbucks has made changes to its board over the past year. Three new members, including the CEOs of YouTube and T-Mobile, Neal Mohan and Mike Sievert, joined earlier this year. This spring, Microsoft CEO Satya Nadella left the board. Spokespeople for Schultz, Starbucks and Elliott declined to comment.</p>


Legal

Management

SBUX

'Howard Schultz Opposes Starbucks Settlement With Activist Investor Elliott' - Financial Times

Offerings

ALRN

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

<p>Paragon Technologies, Inc. ("Paragon"), a diversified holding company and a large shareholder of Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>), ("Company" or "OPT"), issues the following statement to OPT shareholders:</p>
<p>On July 5, OPT filed a proxy statement calling for a special meeting of shareholders on August 30, 2024, asking shareholders to approve increasing the Company's authorized shares to 200 million, up from 100 million.</p>
<p><strong>On July 25, 2025, OPT announced Fiscal 2024 financial results revealing that it lost $27.4 million in fiscal 2024 versus $26.3 million in fiscal 2023.</strong></p>


OPTT

PGNT

Paragon Technologies Recommends Ocean Power Shareholders Vote AGAINST Its Plan To Increase Its Authorized Shares By 100M

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report), VYNE T...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VYNE Therapeutics (VYNE – Research Report), Perspect...

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Perspective Therapeutics (CATX) and SAB Biotherapeutics (SABS)

Perspective Therapeutics to implement reverse stock split

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH – Research Report), Pers...

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Perspective Therapeutics (CATX) and Biogen (BIIB)

Perspective Therapeutics to join Russell 3000 Index

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research Report) an...

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), AbbVie (ABBV)

JonesTrading analyst Justin Walsh has reiterated their bullish stance on CATX stock, giving a Buy rating today. Justin Walsh has given his Buy rati...

Buy Rating Maintained for Perspective Therapeutics Amidst Positive Long-Term Growth Prospects and Upcoming Clinical Catalysts

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), with a pri...

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Radiopharmaceutical Advances

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Nvidia </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a></span>) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%. Surprisingly, there are a few U.S.-listed stocks outperforming Nvidia this year.</p>



<p>Unfortunately, if you only invest in <strong>S&amp;P 500 </strong>stocks, you won&rsquo;t have much in the way of variety. <strong>Super Micro Computer </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/smci-stock-quote/"><strong>SMCI</strong></a></span>) is the only stock among the other 502 in the index that has done better than NVDA. It&rsquo;s up nearly 178%.&nbsp;</p>



<p>Do not despair, the <strong>Russell 2000 </strong>is here to save the day. Of the 2,000 stocks in the small-cap index with a market capitalization over $300 million, there are 31 stocks, that are up more than Nvidia, YTD.&nbsp;</p>



<p>Sadly, only one, <strong>FTAI Infrastructure</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fip-stock-quote/"><strong>FIP</strong></a></span>) has a dividend yield, leaving income investors are out of luck.&nbsp;</p>



<p>With that in mind, here are three stocks outperforming Nvidia so far in 2024, and quite possibly could continue to do so for some time.&nbsp;</p>



<h2>Root (ROOT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/root-stock-man-holding-car-insurance-300x169.jpg" alt="ROOT Stock - Man holding car insurance"><div>Source: Jirsak / Shutterstock.com</div></div><p><strong>Root </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/root-stock-quote/"><strong>ROOT</strong></a></span>) is up 644% year-to-date, more than 4x Nvidia&rsquo;s return. It&rsquo;s certainly been a breakout year for the Insurtech stock. In February, it reported its best Q4 results in its history and the shares gained <a href="https://www.theinsurer.com/news/root-stock-ends-week-up-87-after-best-ever-q4-results/">87%</a> in a single week.&nbsp;</p>



<p>At that point, if you sold thinking it couldn&rsquo;t possibly go any higher, its share price more than doubled over the next five months despite a cooling off in May and June.&nbsp;</p>



<p>On April 30, the technology-enabled insurance company reported its Q1 2024 earnings. Business was very good. As a result, it grew policies-in-force by <a href="https://ir.joinroot.com/static-files/49b07d14-3b03-4fcd-ad03-91a049989d08">101%</a>, to 401,255, while its gross premiums written increased 146% to $331 million. More importantly, it delivered its third consecutive quarter of positive operating cash flow.</p>




<p>&ldquo;By investing in our differentiated technology across our three strategic pillars&mdash;pricing and automation, differentiated distribution, and building a product customers know and love&mdash;we are confident in our ability to realize profitability with existing capital and build meaningful market share long term,&rdquo; stated CEO and co-founder Alex Timm.&nbsp;</p>




<p>While it has an accumulated deficit of $1.72 billion, the rate at which this increases is slowing; a sign that GAAP profitability is just around the corner.&nbsp;&nbsp;&nbsp;</p>



<h2>Perspective Therapeutics (CATX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p><strong>Perspective Therapeutics </strong>(NYSEAMERICAN:<span><a href="https://investorplace.com/stock-quotes/catx-stock-quote/"><strong>CATX</strong></a></span>) is up 221% YTD, 1.4x Nvidia&rsquo;s return.&nbsp;The Seattle-based clinical-stage radiopharmaceutical development company uses its proprietary <a href="https://perspectivetherapeutics.com/about">Pb-212</a> alpha emitting isotope to deliver radiation therapy directly to cancer cells.&nbsp;</p>




<p>&ldquo;Our Radioisotope technology treats tumors on a cellular level when patients are most likely in early stages of cancers. We use proprietary targeting peptides to diagnose tumors, and then deliver Alpha-Particle Radiopharmaceuticals to attack them on a molecular level when the cancer has spread to other sites in the body,&rdquo; <a href="https://perspectivetherapeutics.com/about">states</a> the company&rsquo;s website.&nbsp;</p>




<p>Without getting into the weeds, the company believes using <a href="https://perspectivetherapeutics.com/theranostics">alpha-particles</a> is a more effective radiotherapy than through the use of beta-particle therapies.&nbsp;</p>



<p>The company was established in <a href="https://corridorbusiness.com/medtech-companies-merge-to-form-perspective-therapeutics/">February 2023</a> through the merger between Viewpoint Molecular Targeting and Isoray, both based in Washington State. For each Viewpoint share, shareholders received 3.1642 shares of Isoray stock. Viewpoint shareholders owned 49% of the merged entity with Isoray owning 51%.</p>



<p>With no revenue, except grant revenue, <a href="https://perspectivetherapeutics.com/newsroom/press-release?i=134280">$325,000</a> in Q1 2024, up from $233,000 a year earlier, it had an operating loss of $13.0 million in the quarter, up 33% from $9.8 million a year earlier.&nbsp;</p>



<p>However, thanks to an <a href="https://perspectivetherapeutics.com/newsroom/press-release?i=134656">$80 million</a> secondary offering in May, it finished the month with more than $260 million in cash, cash equivalents and short-term investments. Based on the company&rsquo;s current expenses and research and development spending, it has plenty of cash to burn for the next 24-36 months.&nbsp;&nbsp;</p>



<h2>NuScale Power (SMR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/smr1600-1-300x169.png" alt="Person holding mobile phone with logo of American nuclear power company NuScale Power LLC on screen in front of web page. Focus on phone display. Unmodified photo. SMR stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>NuScale Power </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/smr-stock-quote/"><strong>SMR</strong></a></span>) is up 263% YTD. A big part of the gains has to do with the Bill Gates startup, <a href="https://www.gatesnotes.com/Wyoming-TerraPower-groundbreaking">TerraPower LLC</a>. It&rsquo;s betting big on next-generation nuclear energy.&nbsp;</p>



<p>Although NuScale&rsquo;s history dates back to <a href="https://www.nuscalepower.com/en/about">2002</a> and a university project, it really didn&rsquo;t get going until Fluor became its majority owner in 2011. Its Voygr SMR (small modular reactor) got NRC (Nuclear Regulatory Commission) design approval in 2020. It was the first SMR manufacturer to get NRC design approval.&nbsp;&nbsp;</p>



<p>In May 2022, it went public by <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/modular-reactor-developer-nuscale-completes-spac-merger-starts-trading-on-nyse-70125484">combining</a> with Spring Valley Acquisition Corp., a SPAC (special purpose acquisition company). The merger valued the combined entity&rsquo;s enterprise value at $1.9 billion. It received $380 million in gross proceeds from the transaction. As of Q1 2024, it had <a href="https://www.morningstar.com/stocks/xnys/smr/financials">$132 million</a> in cash and no debt.&nbsp;</p>



<p>On July 10, President Biden signed the Advanced Nuclear for Clean Energy (ADVANCE) Act. The <a href="https://www.world-nuclear-news.org/Articles/President-Biden-signs-ADVANCE-Act-into-law">legislation</a> aims to accelerate the development of innovative nuclear energy assets by making it more financially attractive for participants.&nbsp;</p>



<p>As part of the Act,&nbsp;the federal government will lower the regulatory costs for businesses interested in licensing advanced nuclear reactor technologies and provide financial incentives for companies deploying next-generation nuclear reactor technologies.</p>



<p>Both of these scenarios are good news for NuScale which has yet to generate any significant revenue from its SMR commercialization plans.&nbsp;As Gates would say, &ldquo;Nuclear is the future.&rdquo;&nbsp;&nbsp;</p>



<p><em>On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the </em>InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> </em>Publishing Guidelines</a><em>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or<br>indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/07/3-outperforming-stocks-surpassing-even-nvidia-this-year/">3 Outperforming Stocks Surpassing Even Nvidia This Year</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Perspective Therapeutics

Perspective Therapeutics (CATX) Forecast

Perspective Therapeutics (AMEX:CATX) Stock, Quote.Headers.trade-ideas